DM has been telling us since the Q1 webcast 6 months ago of a second licensing/partnering deal to be announced in 2016. So that imminent deal doesn't seem likely to explain things. The only difference is that on Tuesday he used the word "soon." They've also been close to confirming a second molecule (and stated that they have 6 or 7 promising follow on molecules) since the June Q2 webcast (possibly stated at the Q1 update too, I can't remember). However, DM did say at R&R on Tuesday that “We have already confirmed a 2nd compound, but we have not put it in an IND yet so I didn’t give it a thumbs up.” So they've confirmed, but not confirmed that they've confirmed a second molecule. Nothing has really changed since Q2 other than the BETonMACE clearing the data safety monitoring board back on August 11 and the start of the New Zealand Phase 1 kidney trial on July 21. Perhaps the "catalyst" is time. As we near the close of 2016, the bookends get closer and closer for those unchecked milestones on the 2016 milestone checklist listed on the last slide of the quarterly updates.